Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2010-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbapap.2009.11.008PMID 19922818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

  2010cited by this paper
• RhoGDIβ-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK

  2009cited by this paper
• The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

  2009cited by this paper
• ZAK induces MMP-2 activity via JNK/p38 signals and reduces MMP-9 activity by increasing TIMP-1/2 expression in H9c2 cardiomyoblast cells

  2009cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2009cited by this paper
• The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.

  2009cited by this paper
• Charting the molecular network of the drug target Bcr-Abl

  2009cited by this paper
• Small molecule recognition of c-Src via the Imatinib-binding conformation.

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.

  2008cited by this paper
• Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

  2008cited by this paper
• Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo

  2008cited by this paper
• Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦

  2008cited by this paper
• Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

  2008cited by this paper
• Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.

  2008cited by this paper
• Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors

  2008cited by this paper
• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

  2008cited by this paper
• Developing assays for kinase drug discovery – where have the advances come from?

  2008cited by this paper
• Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation

  2008cited by this paper
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.

  2007cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

  2007cited by this paper
• L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

  2007cited by this paper
• Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

  2006cited by this paper
• NMR characterization of kinase p38 dynamics in free and ligand-bound forms.

  2006cited by this paper
• Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

  2006cited by this paper
• A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain

  2006cited by this paper
• An efficient rapid system for profiling the cellular activities of molecular libraries.

  2006cited by this paper
• AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

  2006cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

  2005cited by this paper
• High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.

  2005cited by this paper
• The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

  2005cited by this paper
• Complete Inhibition of Anisomycin and UV Radiation but Not Cytokine Induced JNK and p38 Activation by an Aryl-substituted Dihydropyrrolopyrazole Quinoline and Mixed Lineage Kinase 7 Small Interfering RNA*

  2005cited by this paper
• Harnessing the power of fireflies and mice for assessing cancer mechanisms

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Regulation of the c-Abl and Bcr–Abl tyrosine kinases

  2004cited by this paper
• Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.

  2004cited by this paper
• Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

  2004cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• Expression of a kinase-defective Eph-like receptor in the normal human brain.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer.

  1995cited by this paper
• WHAT IF: a molecular modeling and drug design program.

  1990cited by this paper
• Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

  1988cited by this paper
• Biological Crystallography Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia

  year unknowncited by this paper

• Atrial fibrillation associated with tyrosine kinase inhibitors: A case-control study of real-world pharmacovigilance data.

  2026cites this paper
• The Coiled Coil and C2 Domains Modulate BCR Localization and BCR-ABL1 Compartmentalization, Transforming Activity and TKI Responsiveness

  2025cites this paper
• New Kinase Inhibitors That Are Selectively Cytotoxic for Tumor Cells

  2025cites this paper
• Nbeal2 Inactivation Triggers Abl1 Stabilisation and Dysregulated Subcellular Localisation of the Multi‐Drug‐Resistant Protein MDR1 (ABCB1) in Mast Cells

  2025cites this paper
• Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.

  2024cites this paper
• Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies

  2024cites this paper
• Novel Electrochemical Approaches for Anticancer Drug Monitoring: Application of CoS@Nitrogen-Doped Amorphous Porous Carbon Composite in Nilotinib Detection

  2024cites this paper
• Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?

  2024cites this paper
• FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants

  2023cites this paper
• Nilotinib alleviates paraquat-induced hepatic and pulmonary injury in rats via the Nrf2/Nf-kB axis.

  2023cites this paper
• Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis

  2023cites this paper
• Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report

  2023cites this paper
• Coronary atherosclerosis and chemotherapy: From bench to bedside

  2023cites this paper
• KinScan: AI-based rapid profiling of activity across the kinome

  2023cites this paper
• Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease.

  2023cites this paper
• Drug repurposing for Basal breast cancer subpopulations using modular network signatures

  2023cites this paper
• Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

  2023cites this paper
• A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.

  2022cites this paper
• The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis

  2022cites this paper
• Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

  2022cites this paper
• Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review

  2022cites this paper
• The Role of Myofibroblasts in Physiological and Pathological Tissue Repair.

  2022cites this paper
• Enhancing autophagy in Alzheimer's disease through drug repositioning.

  2022cites this paper
• Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses

  2022cites this paper
• CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease

  2021cites this paper
• Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

  2021cites this paper
• Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

  2021cites this paper
• Tyrosine Kinases in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis and Potential Therapeutic Role of their Inhibition.

  2021cites this paper
• Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer.

  2021cites this paper
• Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.

  2021cites this paper
• Trends in kinase drug discovery: targets, indications and inhibitor design

  2021cites this paper
• Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts

  2021cites this paper
• Combinatorial therapy in tumor microenvironment: Where do we stand?

  2021cites this paper
• A new stability indicating ultra-fast liquid chromatographic (RP-UFLC) method for the quantification of Nilotinib – A drug for blood cancer

  2021cites this paper
• Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

  2021cites this paper
• Resonance Rayleigh scattering technique-using erythrosine B, as novel spectrofluorimetric method for determination of anticancer agent nilotinib: Application for capsules and human plasma.

  2021cites this paper
• The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success

  2020cites this paper
• Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia

  2020cites this paper
• A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.

  2020cites this paper
• Дерматологические нежелательные явления ингибиторов тирозинкиназы Bcr-Abl

  2020cites this paper
• Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300

  2020influential citation
• c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder

  2020cites this paper
• Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease

  2020cites this paper
• 3D-QSAR Assisted Design of Novel 7-Deazapurine Derivatives as TNNI3K Kinase Inhibitors Using Molecular Docking and Molecular Dynamics Simulation

  2020cites this paper
• Reply to “Cardiovascular Safety of Nilotinib in Alzheimer's Disease”

  2020cites this paper
• Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors

  2020cites this paper
• Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies

  2020cites this paper
• Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma

  2020cites this paper
• A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II-Biological functions and inhibitors.

  2020cites this paper
• Development and Validation of RP-HPLC Method for the Estimation of Nilotinib in Bulk and Pharmaceutical Dosage form

  2020cites this paper
• FORCED DEGRADATION STUDIES OF NILOTINIB HYDROCHLORIDE: ISOLATION, IDENTIFICATION & CHARACTERIZATION OF IMPURITIES

  2020cites this paper
• Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy

  2020cites this paper
• Nilotinib in the treatment of chronic myeloid leukemia.

  2019cites this paper
• What Makes a Kinase Promiscuous for Inhibitors?

  2019cites this paper
• What Makes a Kinase Promiscuous for Inhibitors ? Graphical Abstract Highlights

  2019cites this paper
• [A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia].

  2019cites this paper
• Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment.

  2019cites this paper
• Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

  2019cites this paper
• Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

  2019cites this paper
• Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

  2019cites this paper
• The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system

  2019cites this paper
• Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy

  2018cites this paper
• The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells

  2018cites this paper
• The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

  2018cites this paper
• Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation

  2018influential citation
• HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.

  2018cites this paper
• Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.

  2018cites this paper
• Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.

  2018cites this paper
• Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

  2018cites this paper
• Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

  2018cites this paper
• Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

  2018cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

  2018cites this paper
• Age-related modifications of type I collagen impair DDR1-induced apoptosis in non-invasive breast carcinoma cells

  2018cites this paper
• BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

  2018cites this paper
• Preclinical human models and emerging therapeutics for advanced systemic mastocytosis

  2018cites this paper
• Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial.

  2018cites this paper
• Nilotinib induction of melanogenesis via reactive oxygen species‐dependent JNK activation in B16F0 mouse melanoma cells

  2018cites this paper
• Modulation of d-galactosamine/lipopolysacharride–induced fulminant hepatic failure by nilotinib

  2018cites this paper
• Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension

  2018influential citation
• Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

  2018cites this paper
• Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.

  2017cites this paper
• Investigating the activation mechanism of discoidin domain receptor 1 using advanced microscopy techniques

  2017cites this paper
• Ponatinib reduces viability, migration, and functionality of human endothelial cells

  2017cites this paper
• Current approach to the treatment of chronic myeloid leukaemia.

  2017cites this paper
• Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression

  2017cites this paper
• Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.

  2017cites this paper
• The selective tyrosine kinase-inhibitor nilotinib alleviates experimentally induced cisplatin nephrotoxicity and heptotoxicity.

  2017cites this paper
• Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

  2017cites this paper
• Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia

  2017cites this paper
• GIST: Sequencing Treatment and Case Report Evolution

  2017influential citation
• Fragment-based screening of the oncogenic protein tyrosine phosphatase SHP2

  2017cites this paper
• SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions

  2017cites this paper
• The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

  2017cites this paper
• Discoidin Domain Receptor 1 Mediates Myosin-Dependent Collagen Contraction.

  2017cites this paper
• Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits

  2017cites this paper
• The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

  2017cites this paper
• Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment

  2017cites this paper
• Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia

  2017cites this paper
• Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

  2016cites this paper
• Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy

  2016cites this paper